Eric Yenchi
Psychiatric/Mental Health · Clinton, MDNPI 1346723970
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,058 of the $5,018 with a category attached, or 80.9%. 12 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 24.4% of the total. 2025 is the largest year on record at $2,146, 8.0 times the $269 reported in 2021. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- AbbVie$1K
- Lundbeck LLC$874
- Otsuka America Pharmaceutical, Inc.$595
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$415
- Vanda Pharmaceuticals Inc.$372
- plus $472 from 6 others
What the payments were for
- Consulting fees$96019%
- Food & beverage$4,05881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 17 | $1,226 |
| AbbVie | 58 | $1,065 |
| Lundbeck LLC | 43 | $874 |
| Otsuka America Pharmaceutical, Inc. | 32 | $595 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $415 |
| Vanda Pharmaceuticals Inc. | 12 | $372 |
| Neurocrine Biosciences, Inc. | 11 | $224 |
| Alkermes, Inc. | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Johnson & Johnson | 1 | $30 |
| Gilead | 1 | $30 |
How this compares
$5,018 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 15 | $627 |
| Olanzapine | 38 | $583 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $521 |
| Mirtazapine | 52 | $427 |
| Duloxetine Hcl | 17 | $365 |
| Haloperidol | 14 | $341 |
| Trazodone Hcl | 38 | $285 |
| Prazosin Hcl | 17 | $272 |
| Escitalopram Oxalate | 38 | $272 |
| Hydroxyzine Pamoate | 24 | $259 |
| Fluoxetine Hcl | 70 | $210 |
| Aripiprazole | 11 | $208 |
| Risperidone | 29 | $135 |
| Clonazepam | 34 | $106 |
| Paroxetine Hcl | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Clinton
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.